ICLR - ICON Company Value to Earnings Growth Ratio

Effective delegation of data to cloud services minimizes operational risks for ICON Public (ICLR). The PEG ratio visualizes the resilience of the model, where 10.73 represents the latest metric reading. Long-term contracts with industry behemoths, which remain independent of economic conditions, guarantee stability. Synergy from mergers and partnerships with medical centers accelerates the time-to-market for new drugs.

Metric breakdowns and analytics for ICON (ICLR)

- share price and consensus valuation forecast:

Price Performance Chart ICON Public|ICLR - Consensus Target

- market capitalization statistics:

Market Value ICON Plc|ICLR - Enterprise Value

- book capitalization information:

Net Asset Value per Share ICON|ICLR - Company Book Value|Market Capitalization to Book Value iconplc.com|ICLR - Cumulative Company Assets

- debt obligations and liquidity statistics:

- earnings and multiples data:

ICLR - Company Net Income|Net Profit Forecast ICON Public|ICLR - Price to Earnings Ratio|Future Price to Earnings Multiple ICON Corp|ICLR - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio ICON Plc|ICLR - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) ICON|ICLR - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months iconplc.com|ICLR - Earnings per share growth in current year|Net earnings per share growth forecast for next year ICON Public

General company analysis:ICLR, ICON Plc

For ICON Public (ICLR), whose clinical research operations remain resilient even amid biotech sector R&D budget cuts, this indicator serves as a tool for identifying undervalued assets. By analyzing the weighted PEG ratio, an investor compares the current P/E multiple with net income growth rates, allowing for the identification of the company's fundamental potential regardless of the industry's moderate cyclicality.

Competing companies

IQV (IQVIA Holdings) - Growth-Adjusted Payback Ratio|Laboratory Corporation of America - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio MEDP (Medpace Corp)|Charles River Laboratories - PEG Multiple|Price to Earnings Adjusted for Growth Rate evotec.com|Fortrea (FTRE) - Price/Earnings to Growth Ratio|LFCR - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple OABI|NOTV (Inotiv Corporation) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Ratio Avid Bioservices, Inc. (CDMO)|Growth-Adjusted Market Cap to Net Income catalent.com|PEG Multiple SCPX (Scorpius Holdings)